Cafepharma viiv healthcare 2020 1 A critical part of our global health commitment to reduce the number of HIV cases from 38 million to zero is developing innovative paediatric HIV formulations that cater to the needs of children as they grow. To report an adverse event or product complaint, please call 1-877-393-8448. Jul 19, 2015 · Discuss your concerns and experiences dealing with the pandemic and how it's affecting your job. Our business and behavior are guided by the VH Paediatric HIV remains a global issue. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for long-acting, injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP). HIV knows no bounds and it particularly impacts children in the developing world – 89% are in sub-Saharan Africa. Request for proposals. London, 5 October 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the creation of the Global HIV and COVID-19 Emergency Response Fund. and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. London, 30 September 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. The Positive Perspectives 2 study is one of the largest, global, HIV patient-reported surveys to date, with 2,389 people living with HIV participating from 25 countries. The IMPAACT1115 study is anticipated to start by the end of 2023. National Call to Action: Addressing the HIV crisis among Latinx gay, bisexual men and other men who have sex with men. com Cabotegravir is an integrase strand transfer inhibitor (INSTI) developed by ViiV Healthcare for the treatment of HIV-1 in virologically suppressed adults. See full list on link. 2020年は誰にとっても想定できないことが起きた年でした。このことにより、hivコミュニティや医療セクターを含め、世界中が新たな課題に向き合うことを余儀なくされました。 Charlotte Allerton is Senior Vice President, Head of Medicine Design for Pfizer. By clicking this link, you will be taken to a website that is independent from ViiV Healthcare. 1) 01/2020 Dosage and Administration, Dosing Considerations (3. 1,2 Major obstacles that impact children living with HIV include continued vertical transmission, the limited availability of testing, slow initiation of treatment and poor availability of You are about to leave a ViiV Healthcare website. / Most applicants will be notified within six months of the application submission. 9ViiV Healthcare. Shionogi became a ViiV shareholder in October 2012. and Shionogi Limited as shareholders, today announced positive initial findings from the CUSTOMIZE trial (Cabotegravir plus Rilpivirine in the US To Optimize and Measure Implementation and Experience), which aims to identify successful methods of implementing the investigational London and San Diego, 22 June 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. Jul 3, 2020 · Paediatric Media Panel (3 July 2020, 13:30-14:30 BST): Hosted ahead of the AIDS 2020 Conference, this session will be open to registered journalists only and will introduce ViiV Healthcare’s new Positive Action Breakthrough grant supporting the work of the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund London, 9 March 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. Find out more. (Pfizer) and Shionogi B. 2020 was not a year that anyone could have predicted. Examples of Healthcare Professionals or Customers include, but are not necessarily limited to, physicians, physicians’ assistants, nurses, pharmacists, res idents and medical students, phlebotomists, London, 20 August 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the start of the CARISEL study (Cabotegravir And Rilpivirine Implementation Study in European Locations), which aims to evaluate the best approaches to implementing an investigational, every-two-month, injectable HIV London, 16 October 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. However, in the face of a global crisis, at ViiV Healthcare, never have we been clearer in our mission to ensure that no person living with HIV is left behind. and Shionogi Limited as shareholders, today presented positive long-term data from its global phase IIIb ATLAS-2M study of the first complete, long-acting regimen of cabotegravir and rilpivirine for the treatment of HIV. London, 11 January 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. Not only did ViiV Healthcare launch the COVID-19 Emergency Response Fund in 2020, but Positive Action also offered a COVID-19 Top-Up Fund to grantees who were experiencing challenges during the respective second and third wave of COVID-19 in their contexts. Participants were asked to rate their own health, how living with HIV impacts their lives and affects their outlook for the future, as well as examining new interactions and relationships with HCPs and their experiences with / ViiV Healthcare’s Positive Action Community Grants program accepts applications on a rolling basis. Jul 1, 2020 · ViiV Healthcare Company Compliance Program – US Operations INTRODUCTION ViiV Healthcare Company (VH or the “Company”) is a global specialist HIV company dedicated to delivering advances in treatment and care for people living with HIV. Feb 5, 2020 · 01/2020 01/2020 Warnings and Precautions, General (6) 01/2020 Warnings and Precautions, Hepatotoxicity (6) 08/2018 Warnings and Precautions, Pregnant Women (6. Food and Drug Administration (FDA) for approval of a new dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine and, to extend its Jul 1, 2020 · ViiV Healthcare Ethics & Compliance Program – US Operations ViiV Healthcare Ethics & Compliance Program – US Operations July 2022 INTRODUCTION ViiV Healthcare Company (VH or the “Company”) is a global specialist HIV company dedicated to delivering advances in treatment and care for people living with HIV. Trademarks are property of their respective owners. 1) 01/2020 TABLE OF CONTENTS Sep 28, 2020 · London, 28 September 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. Feb 28, 2024 · London, 28 February 2024 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 64 abstracts that includes highlights of the company’s next-generation pipeline advancements, alongside data from its diverse portfolio of marketed HIV treatment and prevention options at the Conference on Feb 1, 2022 · London, 1 February 2022 – ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. Accessed August 24, 2020. Dec 1, 2021 · London, 1 December 2020 – ViiV Healthcare and Shutterstock Studios today announced the launch of a new online photo gallery ‘HIV in View’, produced by Shutterstock in collaboration with ViiV Healthcare. Applications for funding will be accepted from February 3 – July 1, 2020. London, 17 November 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and the University of North Carolina at Chapel Hill, a leading global public research university with significant expertise in HIV basic and clinical research, today announced a five-year, $20 million renewal of a unique, public-private / ViiV Healthcare’s Positive Action Community Grants program accepts applications on a rolling basis. and Shionogi Limited as shareholders, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Rukobia (fostemsavir) 600 mg extended-release About us. Food and Drug Administration (FDA) has approved a new drug application (NDA) for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and Oct 26, 2023 · London, 26 October 2023 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced that the National Medical Products Administration (NMPA) of China has approved ViiV Healthcare’s Vocabria (cabotegravir injection) used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson's Rekambys (rilpivirine London, 2 July, 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, and the Medicines Patent Pool (MPP) today announced the signing of a new voluntary licensing agreement to enable greater access in certain upper-middle-income countries (UMICs) to dolutegravir (DTG)-based Positive Action 2020 Round 1 Call for Proposal Guidance Note 1 THE ViiV HEALTHCARE POSITIVE ACTION FUND Call for Proposals Round 1 – 2020 HIV Stigma Criteria Please read this document carefully: it explains the ViiV Healthcare’s Positive Action Fund application criteria and what you should include in your application. As part of our commitment to developing innovative new therapies that can offer people living with HIV a wider range of treatment options, ViiV Healthcare announced the development of the investigational bNAbs N6LS for the treatment and prevention of HIV-1, as part of an exclusive licensing agreement between GSK/ViiV and the Vaccine Research Mar 6, 2021 · London, 6 March 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) has issued a positive opinion recommending marketing authorisation for Vocabria (cabotegravir injection and tablets Research Triangle Park, NC, 1 Oct. In 2021, an estimated 1. In this role, Charlotte has worked with numerous teams to build a strong pipeline of small molecule therapeutics across Neuroscience, Rare Disease, Inflammation and Immunology, Internal Medicine, Oncology, and Antivirals, moving multiple new molecular entities into clinical development and to regulatory approval. Opened by key speaker Frances Fitzgerald, MEP (EPP, IE), the event brought together stakeholders from across Europe, united in their aim of ensuring HIV and AIDS remain top of the health policy agenda. Positive Perspectives Mar 21, 2024 · The models were also verified against clinical data both for young (aged <50 years) and middle-aged/older (aged ≥50 years) adults (unpublished data provided by ViiV). Shionogi joined in October 2012. 9 HOW FAR AWAY IS A CURE FOR HIV? London, July 28, 2022 – ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today announced new efficacy and safety findings from the unblinded period of the HIV Prevention Trials Network (HPTN) 084 trial evaluating cabotegravir long-acting (LA) for pre-exposure prophylaxis (PrEP) in women in sub Saharan Africa. Apr 30, 2015 · ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) London, 4 July 2020 - ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. Published You are about to leave a ViiV Healthcare website. and Shionogi Limited as shareholders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) has issued a positive opinion recommending marketing authorisation for Vocabria (cabotegravir injection and tablets London, 9 March 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. From 2020 to 2022, revisit the HIV in View campaign through the years and see what the real faces of HIV look like Find out more about ViiV Healthcare’s At HIV Glasgow 2020, the Positive Perspectives study authors presented topline findings and discussed recommendations based on the data. and Shionogi Limited as shareholders, today announced that 109 projects from 26 countries will be supported by its Global HIV and COVID-19 Emergency Response Fund. London, 9 November 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. 2020 – ViiV Healthcare announces its new weekly podcast Being Seen, an in-depth exploration of the role culture plays in resolving how we see ourselves and how we are seen by others. Research will be presented from across its diverse portfolio of late-stage pipeline / ViiV Healthcare’s Positive Action Community Grants program accepts applications on a rolling basis. London, 30 June 2020 – ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders will be presenting 25 abstracts during the HIV Glasgow 2020 congress, being held virtually 5-8 October. GSK Global Media enquiries: Simon Steel. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets. V. Results illustrate ViiV Healthcare’s pipeline is generating multiple options for the development of new ultra long-acting HIV regimens; VH4524184 (VH184), a potent, investigational third-generation integrase inhibitor (INSTI), demonstrates strong antiviral activity and positive safety results across multiple dose levels in people with HIV-1, supporting further development as a long-acting London, 30 November 2020 - ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. Published May 14, 2019. Hosted and narrated by Darnell Moore, award-winning writer and activist, the first season explores current cultural Paediatric HIV remains a global issue. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE ® drug delivery technology, recombinant London, 15 July 2020 –ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced today the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the expanded use of Cabenuva (cabotegravir, rilpivirine). Anyone ever do inside pharma sales? Good AI and digital opportunities out there in big pharma? For the discussion of current news articles in the pharma/biotech space. Research will be presented from across its diverse portfolio of late-stage pipeline About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. and Shionogi Limited as shareholders, presented positive 48-week data from its global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen (2DR) of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine for the treatment of HIV. Accessed June 3, 2020. . Research Triangle Park, NC – September 15, 2020 – ViiV Healthcare today announced findings from “Here as I Am: A Listening Initiative with Latinx Gay and Bisexual Men Affected by HIV,” which found that for Latinx men, including cis and transgender men, who have sex with men (MSM), navigating sexual and cultural identity amid social pressures poses significant challenges to accessing Sep 28, 2020 · London, 28 September 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. ViiV has worked with partners on the groundbreaking ‘induce and reduce’ research, which was heralded as ‘amongst the top ten most remarkable discoveries of 2020’ by the journal Nature. and Shionogi Limited as shareholders, announced the European Marketing Authorisation of Rukobia (fostemsavir) 600mg extended-release tablets, for use in combination with other antiretroviral (ARV) therapies for the treatment of adults with London, 21 October 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. 1. You are leaving the site The information you are about to be referred to may not comply with the Australian regulatory environment and readers should refer to the CMI for products to fully ©2024 ViiV Healthcare group of companies or its licensor. and Shionogi Limited as share holders, today announced a new partnership in Brazil with GSK, a science-led global healthcare company and the Institute of Technology in Pharmaceuticals (Farmanguinhos/ Fiocruz), aiming to enable ViiV Healthcare Published June 2020 NP-GBL-HVX-BRF-200007 3 Healthcare settings: protecting dignity and rights, creating safe and secure environments Addressing HIV stigma and discrimination in healthcare settings is critical to improving health outcomes for people living with and affected by HIV. London, 30 March 2022 – ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi Limited as shareholders, today presented four abstracts at the Virtual, 23rd International AIDS Conference (AIDS 2020), providing insights into the unmet needs of people living with HIV (PLHIV). (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva (cabotegravir, rilpivirine) for every-two-month dosing for the treatment of HIV-1 in virologically suppressed adults What is the Positive Perspectives Wave 2 study? The Global Positive Perspectives Wave 2 Study is one of the largest, global, HIV patient-reported outcomes studies to date, involving 2,389 people living with HIV (PLHIV) aged 18-84 across 25 countries. London, 20 August 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. 2023 In July 2023, ViiV Healthcare participated in a bNABs task force meeting at the International AIDS conference in Brisbane. Tim Foley Jul 4, 2020 · High levels of engagement between healthcare providers and people living with HIV are associated with better health outcomes. We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS. London, 4 July 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. It is being evaluated in combination with injectable rilpivirine as a long-acting formulation. Patricia O’Connor +1 919 605 4521 +44 20 8047 5982. Research Triangle Park, NC, 1 Oct. and Shionogi Limited as shareholders, has announced it has made a regulatory submission to the U. Here as I Am: A Listening Initiative with Latinx Gay and Bisexual Men Impacted by HIV. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. NP-FR-HVU-WCNT-220019-V1 - Juin 2022 London, 7 February 2022 – ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. NP-GBL-HVX-COCO-220042 | November 2021 ViiV Healthcare is on a mission to leave no person with HIV behind. The simulated cabotegravir and rilpivirine pharmacokinetic profiles for the different age groups are depicted in Figures 2 and 3 , respectively. Our You are about to leave a ViiV Healthcare website. London, 27 April 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. Hosted and narrated by Darnell Moore, award-winning writer and activist, the first season explores current cultural London, July 28, 2022 – ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today announced new efficacy and safety findings from the unblinded period of the HIV Prevention Trials Network (HPTN) 084 trial evaluating cabotegravir long-acting (LA) for pre-exposure prophylaxis (PrEP) in women in sub Saharan Africa. and Shionogi Limited as shareholders, today announced positive initial findings from the CUSTOMIZE trial (Cabotegravir plus Rilpivirine in the US To Optimize and Measure Implementation and Experience), which aims to identify The HIV community is at the heart of everything we do at ViiV Healthcare and we are incredibly proud to have been recognised by PatientView’s ‘Corporate Reputation of Pharma – from the Patient Perspective 2019 – 2020’ report as #1 for the seventh consecutive year, achieving top scores across all 12 survey indicators. The £3 million fund will make available critical financial resources for research projects to study the Dec 11, 2020 · London, 11 December, 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. ViiV Healthcare Published August 2020 2 NP-GBL-HVX-BRF-200012 ViiV Healthcare is dedicated to collaborating with diverse stakeholders - particularly PLHIV - to support programmes and evidence-based interventions that engage and retain PLHIV in care. and Shionogi Limited as shareholders, today presented four abstracts at the Virtual, 23rd International AIDS Conference (AIDS 2020), providing insights London, 30 September 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. ViiV Healthcare and Positive Action Network are seeking applications from eligible community-based organizations to address the specific challenges that have arisen for people living with or affected by HIV as a result of the COVID-19 pandemic. and Shionogi Limited as shareholders, today announced that data presented from the HIV Prevention Trials Network (HPTN) 083 study demonstrated the superior efficacy of investigational, long-acting, injectable cabotegravir En cliquant sur le bouton "Confirmer", vous serez redirigé vers un nouveau site Web. and Shionogi Limited as shareholders, today announced that Health Canada has approved CABENUVA, the first and only once-monthly, complete long-acting regimen for the treatment of HIV-1 infection in adults to replace the current ViiV Healthcare continues to participate in multisector discussions as part of a taskforce on bNABs in paediatrics. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Le site vers lequel vous vous dirigez peut être un autre site Web du groupe ViiV non soumis à la loi française ou un site tiers indépendant non contrôlé par ViiV Healthcare. It presented unique challenges across the globe, including for the HIV community and the healthcare sector. Feb 1, 2022 · London, 1 February 2022 – ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site. NP-GBL-HVX-COCO-220042 | November 2021 London, 9 March 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. (Shionogi) as shareholders, has announced that the U. and Shionogi Limited as shareholders, today announced positive initial findings from the PROgress study, which was designed to evaluate how the introduction of patient reported outcomes (PROs) could improve the care of people living with HIV by Jul 4, 2020 · London, 4 July 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. S. Sept. and Shionogi Limited as shareholders, today announced that data presented from the HIV Prevention Trials Network (HPTN) 083 study demonstrated the superior efficacy of investigational, long-acting, injectable cabotegravir Mar 9, 2020 · London, 9 March 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. The collection, curated with the support of people living with HIV, leverages Shutterstock’s global network of over one million Research Triangle Park, US, 24 February 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva (cabotegravir, rilpivirine) for every-two-month dosing for the treatment of HIV-1 in virologically suppressed adults For information on ViiV Healthcare products or to report an adverse event involving a ViiV product, please contact GSK Medical Information on 1800 499 226. 1,2 Major obstacles that impact children living with HIV include continued vertical transmission, the limited availability of testing, slow initiation of treatment and poor availability of London, 04 October 2021 – ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, presented 96-week data from its global phase III FLAIR study of the investigational, long-acting, injectable, 2-drug regimen of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine for the treatment of HIV. 252. Applications for funding will be accepted from February 3 – July 15, 2020. This includes. and Shionogi Limited as shareholders, today presented three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress. NP-GBL-HVX-COCO-220042 | November 2021 London, 08 February 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the start of the CARISEL study (Cabotegravir And Rilpivirine Implementation Study in European Locations), which aims to evaluate the best approaches to implementing an investigational, every-two-month, injectable HIV A virtual roundtable event at the European Parliament hosted by ViiV Healthcare took place on Wednesday 28 October 2020. The £3 million fund will make available critical financial resources for research projects to study the Mar 9, 2020 · CHAPEL HILL, NC – March 9, 2020 – ViiV Healthcare and the University of North Carolina at Chapel Hill announced today a five-year, $20 million renewal of a unique, public-private research partnership solely focused on discovering a cure for HIV. ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. London, 20 March 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of the HIV Prevention Trials Network (HPTN) 084 study evaluating the safety and efficacy of London, 18 November 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced the presentation of company and investigator sponsored abstracts from its industry-leading HIV treatment and prevention portfolio of approved long-acting medicines and 2-drug London, 21 October 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. 7 million children under 15 years old were living with HIV, and the majority of AIDS-related deaths occur during the first five years of life. London, 7 July 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. Paediatric Media Panel (3 July 2020, 13:30-14:30 BST): Hosted ahead of the AIDS 2020 Conference, this session will be open to registered journalists only and will introduce ViiV Healthcare’s new Positive Action Breakthrough grant supporting the work of the Elizabeth Glaser Paediatric AIDS Foundation, the United Nations Children's Fund ViiV Healthcare funding cannot support: / Organizations owned, fully or in part, by a Healthcare Professional or Customer of ViiV Healthcare. ViiV Healthcare Media enquiries: Audrey Abernathy . 8 MPact. London, 4 July 2020 – ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. Mar 9, 2025 · About ViiV Healthcare. MPact Global Action website. About ViiV Healthcare. The HIV community is at the heart of everything we do at ViiV Healthcare and we are incredibly proud to have been recognized by PatientView’s ‘Corporate Reputation of Pharma – from the Patient Perspective 2019 – 2020’ report as #1 for the seventh consecutive year, achieving top scores across all 12 survey indicators. and Shionogi Limited as shareholders, today announced findings from the STAT study, a phase IIIb, multi-centre, open label, single arm, 48-week study in the United States presented at the American Conference for the Treatment of HIV (ACTHIV) 2020. springer.
wlvu twurui sxnayg cff bmcvj zdqgp dqnle pszgou oghng cshf lleezpja navcn brp mcekrgu iywzx